The role of bisphosphonates in breast cancer
- 31 December 2004
- journal article
- review article
- Published by Elsevier in The Breast
- Vol. 13 (1) , 19-28
- https://doi.org/10.1016/j.breast.2004.09.004
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Assessing Tumor-Related Signs and Symptoms to Support Cancer Drug ApprovalJournal of Biopharmaceutical Statistics, 2004
- Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnnals of Oncology, 2003
- Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinomaCancer, 2003
- End Points and United States Food and Drug Administration Approval of Oncology DrugsJournal of Clinical Oncology, 2003
- Management of Metastatic Bone Disease and Hypercalcemia of MalignancyAmerican Journal of Cancer, 2003
- Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical EndpointsAmerican Journal of Clinical Oncology, 2002
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001
- Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasesCancer, 2000
- Skeletal complications of malignancyCancer, 1997
- Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compoundJournal of Bone and Mineral Research, 1994